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Chronic Obstructive Pulmonary Disease (COPD) is a type of lung disease 
by a decline in lung function over time in which subsets of patients may 
have dominant features of chronic bronchitis and/or emphysema 
characterized by long-term  airflow obstruction that is not fully 
reversible with the main symptoms include shortness of breath and 
cough with sputum production typically worsens over time, some 
significant extra-pulmonary effects, and important comorbidities which 
may contribute to the severity of the disease in individual patients. 
Chronic bronchitis is defined clinically as the presence of a chronic 
productive cough for 3 months during each of 2 consecutive years (other 
causes of cough being excluded).
Emphysema is defined as an abnormal, permanent enlargement of the 
air spaces distal to the terminal bronchioles, accompanied by 




• Globally, as of 2010, COPD affected approximately 329 million people 
(4.8% of the population)
• In England, an estimated 0.84 million people (of 50 million) have a 
diagnosis of COPD; this translates into approximately one person in 
59 receiving a diagnosis of COPD at some point in their lives
• In the United States approximately 6.3% of the adult population, 
totaling approximately 15 million people, have been diagnosed with 
COPD 
• The disease affects men and women almost equally, as there has 
been increased tobacco use among women in the developed world
• COPD is more common in older people 





COPD - Deaths / 1000 1990 Data projected to 2000.
Epidemiology
http://dm5migu4zj3pb.cloudfront.net/manuscripts/33000/33947/medium/JCI0833947.f2.jpg
Chronic Obstructive Pulmonary Disease Among Adults Aged 18 and 
Over in the United States, 1998–2009.
Risk Factors and Etiology    
• Smoking: smokers are 13 times more likely to die from the COPD
• Air Pollution: indoor and outdoor pollutants
• Occupational Dusts and Chemicals: industrial dust, chemicals, and 
gases
• Genetics: in rare cases, genetic factors can cause people who have 
never smoked (a lack of the protein α1-antitrypsin (AAT), Salla 
disease, etc.)
• Intravenous drug use: the pulmonary vascular damage that results 
from the insoluble filler contained in methadone or methylphenidate 
• Connective tissue disorders: Cutis laxa, Marfan syndrome, Ehlers-
Danlos syndrome, Vasculitis syndrome, etc.
• Immunodeficiency syndromes
• Age: incidence COPD increases with age.
http://www.healthline.com/health/copd/risk-factors#Overview1
Risk Factors and Etiology  
https://www.consumerhealthdigest.com/wp-content/uploads/2015/01/smoking-asthma.jpg
Mechanism                                         
General 1
• Pathologic changes in COPD occur in the large (central) airways, the 
small (peripheral) bronchioles, and the lung parenchyma
• Most cases of COPD are the result of exposure to noxious stimuli, 
most often cigarette smoke
• The normal inflammatory response is amplified in persons prone to 
COPD development
• Increased numbers of activated polymorphonuclear leukocytes and 
macrophages release elastases in a manner that cannot be 
counteracted effectively by antiproteases, resulting in lung 
destruction  
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3
Mechanism                                         
General 2
• The primary offender has been found to be human leukocyte 
elastase, with synergistic roles suggested for proteinase-3 and 
macrophage-derived matrix metalloproteinases (MMPs), cysteine 
proteinases, and a plasminogen activator
• Additionally, increased oxidative stress caused by free radicals in 
cigarette smoke, the oxidants released by phagocytes, and 
polymorphonuclear leukocytes all may lead to apoptosis or necrosis 
of exposed cells
• Accelerated aging and autoimmune mechanisms have also been 
proposed    
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3
Mechanism                                         
General 2
• Cigarette smoke causes neutrophil influx, which is required for the 
secretion of MMPs; this suggests, that neutrophils and macrophages 
are required for the development of emphysema 
• In addition to macrophages, T lymphocytes, particularly CD8+, play an 
important role in the pathogenesis of smoking-induced airflow 
limitation 
• The dysregulation of apoptosis and defective clearance of apoptotic 
cells by macrophages play a prominent role in airway inflammation, 
particularly in emphysema 
• In patients with stable COPD without known cardiovascular disease, 
there is a high prevalence of microalbuminuria, which is associated 
with hypoxemia independent of other risk factors.
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3




Mechanism                                           
Schema 2
Multifaceted mechanisms in COPD.
http://www.nature.com/nri/journal/v8/n3/images/nri2254-f2.jpg
Mechanism                                         
Chronic Bronchitis 1
• Mucous gland hyperplasia is the histologic hallmark of chronic 
bronchitis
• Airway structural changes include atrophy, focal squamous 
metaplasia, ciliary abnormalities, variable amounts of airway smooth 
muscle hyperplasia, inflammation, and bronchial wall thickening
• Damage to the endothelium impairs the mucociliary response that 
clears bacteria and mucus
• Inflammation and secretions provide the obstructive component of 
chronic bronchitis
• Neutrophilia develops in the airway lumen, and neutrophilic 
infiltrates accumulate in the submucosa 
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3
Mechanism                                         
Chronic Bronchitis 2
• The respiratory bronchioles display a mononuclear inflammatory 
process, lumen occlusion by mucus plugging, goblet cell metaplasia, 
smooth muscle hyperplasia, and distortion due to fibrosis 
• These changes, combined with loss of supporting alveolar 
attachments, cause airflow limitation by allowing airway walls to 
deform and narrow the airway lumen 
• In contrast to emphysema, chronic bronchitis is associated with a 
relatively undamaged pulmonary capillary bed
• Eventually, hypercapnia and respiratory acidosis develop, leading to 
pulmonary artery vasoconstriction and cor pulmonale.
• With the ensuing hypoxemia, polycythemia, and increased 
CO2 retention, these patients have signs of right heart failure and are 
known as "blue bloaters."
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3
Mechanism                                           
Schema 3
http://img.tfd.com/MosbyMD/thumb/bronchitis.jpg spiriva.com/img/content/reduced-airflow.jpg
Mechanism                                           
Schema 4
http://www.who.int/respiratory/copd/GOLD_WR_06.pdf
Mechanisms Underlying Airflow Limitation in COPD.
Mechanism                                         
Emphysema 1
• Emphysema is a diagnosis defined by permanent enlargement of 
airspaces distal to the terminal bronchioles
• This leads to a dramatic decline in the alveolar surface area available 
for gas exchange
• Loss of alveoli leads to airflow limitation by 2 mechanisms: 1) loss of 
the alveolar walls results in a decrease in elastic recoil, which leads to 
airflow limitation, 2) loss of the alveolar supporting structure leads to 
airway narrowing, which further limits airflow 
• Emphysema has 3 morphologic patterns: centriacinar, panacinar, 
distal acinar (paraseptal) 
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3
Mechanism                                         
Emphysema 2
• Centriacinar emphysema is characterized by focal destruction limited 
to the respiratory bronchioles and the central portions of the acini 
• Panacinar emphysema involves the entire alveolus distal to the 
terminal bronchiole 
• Distal acinar emphysema is the least common form and involves 
distal airway structures, alveolar ducts, and sacs 
• The gradual destruction of alveolar septae and of the pulmonary 
capillary bed in emphysema leads to a decreased ability to oxygenate 
blood
• The body compensates with lowered cardiac output and 
hyperventilation 
• Eventually, patients develop muscle wasting and weight loss and are 
identified as "pink puffers.“
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3




International Classification of Diseases  
https ://www.tsoshop.co.uk/productimages/default.aspx?ISBN=9789241549165&FORMAT=3  http://apps.who.int/classifications/icd10/browse/2016/en#/XI
• X Diseases of the respiratory system
• Chronic lower respiratory diseases
(J40-J47)
• J40 Bronchitis, not specified as acute or chronic
• J41 Simple and mucopurulent chronic bronchitis
• J42 Unspecified chronic bronchitis
• J43 Emphysema
• J44 Other chronic obstructive pulmonary disease
• J45 Asthma
• J46 Status asthmaticus
• J47 Bronchiectasis
Classification                                         
GOLD staging of severity for COPD, based on the value of FEV1
https ://www.merckmanuals.com/professional/pulmonary-disorders/pneumonia/overview-of-pneumonia
Stage I Mild COPD FEV1/FVC<0.70 FEV1≥ 80% normal
Stage II Moderate 
COPD
FEV1/FVC<0.70 FEV1 50-79% normal
Stage III Severe COPD FEV1/FVC<0.70 FEV1 30-49% normal
Stage IV Very Severe 
COPD
FEV1/FVC<0.70 FEV1 <30% normal, or <50% 
normal with chronic 
respiratory failure present*
* Usually, this means requiring long-term oxygen therapy.
Classification                                 
Clinical GOLD staging of COPD severity
• Stage 0: at risk; chronic cough and sputum production; spirometry is 
normal
• Stage I: mild COPD; mild airflow limitation (FEV1/FVC) less than 70% 
but FEV1 80% or more than predicted; usually, but not always, 
chronic cough and sputum production
• Stage II: moderate COPD; worsening airflow limitation (FEV1 50-79% 
predicted) and usually progression of symptoms, with shortness of 
breath, especially on exertion
• Stage III: severe COPD; further worsening of airflow limitation (FEV1 
30-50% predicted), increased shortness of breath, and repeated 
exacerbations
• Stage IV: very severe COPD; severe airflow limitation (FEV1 less than 
30% predicted) or the presence of chronic respiratory failure
http://patient.info/doctor/chronic-obstructive-pulmonary-disease-pro
Classification                                Severity 
staging of airflow obstruction according to the American 
Thoracic Society (ATS)/European Respiratory Society (ERS)
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/
Mild FEV1/VC <5th percentile of predicted and FEV1 ≥70% pred
Moderate FEV1/VC <5th percentile of predicted and FEV1 60–69% pred
Moderately 
severe
FEV1/VC <5th percentile of predicted and FEV1 50–59% pred
Severe FEV1/VC <5th percentile of predicted and FEV1 35–49% pred
Very severe FEV1/VC <5th percentile of predicted and FEV1 <35% pred
FEV1: forced expiratory volume in 1 second; VC: vital capacity; % 
pred: % of predicted value; FVC: forced vital capacity.
Symptoms and Signs
• The most important symptoms of COPD are breathlessness on 
exertion and chronic cough with or without phlegm
• The dyspnea usually worsens over time but is often not present in 
mild or moderate COPD
• The cough may be dry or productive
• Cough and phlegm often precede dyspnea on exertion by many years
• Other symptoms include wheezing and chest tightness
• As the disease progresses and reaches the severe stages, fatigue, 
weight loss and anorexia may increase. 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/
Clinical Manifestations 1
• A characteristic of COPD is exacerbations or episodes of acute 
worsening of the respiratory symptoms.
• The most common causes of exacerbations are viral or bacterial 
infections
• Increased air pollution also appears to precipitate exacerbations of 
COPD
• Some patients are particularly prone to exacerbations while others 
are not
• Two or more exacerbations during the previous year is the most 
important indicator of a future exacerbation 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/
Clinical Manifestations 2
• Exacerbations accelerate the decline in lung function that 
characterises COPD, resulting in reduced physical activity, poorer 
quality of life, and an increased risk of death; they are also 
responsible for a large proportion of the healthcare costs attributable 
to COPD 
• Patients with COPD often suffer from other diseases (comorbidities) 
• The comorbidities may share common risk factors with COPD, in 
particular cigarette smoking, and may also represent extrapulmonary 
manifestations or complications of COPD, such as muscle dysfunction 
due to inactivity
• Comorbidities may be secondary to treatment of COPD; for example, 
osteoporosis due to oral corticosteroid treatment 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/
Clinical Manifestations 3
• The most common comorbidities in COPD are ischemic heart disease, 
anxiety and depression, osteoporosis, skeletal muscle dysfunction, 
gastro-esophageal reflux, anaemia, lung cancer, diabetes and 
metabolic syndrome
• Comorbidities contribute to the overall severity and manifestations of 
the disease and can occur in mild, moderate or severe COPD  
• The clinical effects of COPD show considerable inter-individual 
variation, depending on which respiratory symptoms predominate, 
the frequency of exacerbations, the level and rate of lung function 
decline and the amount of emphysema, as well as comorbidities.














• The diagnosis of COPD should be considered in anyone over the age 
of 35 to 40 who has shortness of breath, a chronic cough, sputum 
production, or frequent winter colds and a history of exposure to risk 
factors for the disease
• Spirometry is then used to confirm the diagnosis.
• The formal diagnosis of COPD is made, when the ratio of forced 
expiratory volume in 1 second over forced vital capacity (FEV1/FVC) is 
less than 70% of that predicted for a matched control, it is diagnostic 
for a significant obstructive defect 
• Screening those without symptoms is not recommended. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Signs_and_symptoms
Diagnosis                                             
Spirometry 1
http://www.medscape.org/viewarticle/741196
PEFR = peak expiratory flow rate; TLC = total lung capacity.
Diagnosis                                             
Spirometry 2
http://image.slidesharecdn.com/copyofslsqasthmamanagementpptv050811piccomp-141113083910-conversion-gate02/95/spirometry-basics-2-30-638.jpg?cb=1415868230
Diagnosis                                             
Spirometry 3
http://a360-wp-uploads.s3.amazonaws.com/wp-content/uploads/rtmagazi/2011/10/10-01_02.jpg
Diagnosis                                            
Arterial Blood Gas (ABG) Findings
• ABGs provide the best clues as to acuteness and severity of disease 
exacerbation
• Patients with mild COPD have mild to moderate hypoxemia without 
hypercapnia
• As the disease progresses, hypoxemia worsens and hypercapnia may 
develop, with the latter commonly being observed as the FEV 1 falls 
below 1 L/s or 30% of the predicted value
• pH usually is near normal; a pH below 7.3 generally indicates acute 
respiratory compromise
• Chronic respiratory acidosis leads to compensatory metabolic 
alkalosis.
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Diagnosis                                             
Frontal And Lateral Chest Radiographs
• Flattening of the diaphragm
• Increased retrosternal air space
• A long, narrow heart shadow
• Rapidly tapering vascular shadows accompanied by hyperlucency of 
the lungs
• Radiographs in patients with chronic bronchitis show increased 
bronchovascular markings and cardiomegaly.
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Diagnosis                                             
Imaging Studies  1
https://images.radiopaedia.org/images/266487/d35992af9e42aba7d71001c13843c3_jumbo.jpg
Diagnosis                                             
Imaging Studies  2
http://thoracicandsleep.com.au/wp-content/uploads/2015/10/copd-medical-imaging.jpg
Diagnosis                                              
High-Resolution Computed Tomography
• Greater sensitivity than standard chest radiography
• High specificity for diagnosing emphysema (outlined bullae are not 
always visible on a radiograph)
• May provide an adjunctive means of diagnosing various forms of 
COPD (e.g., lower lobe disease may suggest alpha1-antitrypsin (AAT) 
deficiency
• May help the clinician determine whether surgical intervention would 
benefit the patient.
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Diagnosis                                             
Imaging Studies  3
https://images.radiopaedia.org/images/266487/d35992af9e42aba7d71001c13843c3_jumbo.jpg
Diagnosis                                             
Imaging Studies  4
http://www.radiologyassistant.nl/data/bin/w440/a5097977c9caf7_rb1.jpg
Diagnosis                                              
Other Tests
• Hematocrit (patients with polycythemia)
• Serum potassium (diuretics, beta-adrenergic agonists, and 
theophylline act to lower potassium levels)
• Measure AAT in patients  < 40 years or with a family history of 
emphysema at an early age
• Sputum evaluation (a transformation from mucoid in stable chronic 
bronchitis to purulent in acute exacerbations)
• Pulse oximetry provides instant feedback on a patient's status
• Electrocardiography can establish that hypoxia is not cardiac
• The distance walked in 6 minutes is a predictor of mortality in 
patients with moderate COPD
• Right-sided heart catheterization can confirm pulmonary artery 
hypertension.
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Diagnosis                                              
Differentiation
http://patient.info/doctor/chronic-obstructive-pulmonary-disease-pro
• Asthma: diagnosed by establishing reversibility or variability of 
airflow obstruction either by spirometry or peak flow measurements 
after treatment with a bronchodilator or steroid 
• Other diagnoses to consider are congestive heart failure, 
bronchiectasis, allergic fibrosing alveolitis, pneumoconiosis, 
asbestosis or other restrictive lung conditions, tuberculosis, lung 
cancer, obliterative bronchiolitis, bronchopulmonary dysplasia, 
anaemia or generally poor physical condition.
Management
• Assessment and monitoring of disease, reduction of risk factors, 
management of stable COPD, management of exacerbations
• The goals of management are to relieve symptoms, prevent disease 
progression, improve exercise tolerance, improve health status, 
prevent and treat complications and exacerbations, reduce mortality 
and prevent or minimize side-effects from treatment  
• Important components of management are smoking cessation, 
medical treatment with bronchodilators as well as inhibitors of 
inflammation, physical exercise and, in advanced disease, oxygen 
therapy, influenza vaccination once a year, pneumococcal 
vaccination once every 5 years
• Pulmonary rehabilitation is important, the most effective component 
of pulmonary rehabilitation is physical exercise. 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/
Management                                     
Approaches to Management by COPD Stage
• Stage I (mild obstruction): short-acting bronchodilator as needed
• Stage II (moderate obstruction): short-acting bronchodilator as 
needed; long-acting bronchodilator(s); cardiopulmonary rehabilitation
• Stage III (severe obstruction): short-acting bronchodilator as needed; 
long-acting bronchodilator(s); cardiopulmonary rehabilitation; inhaled 
glucocorticoids if repeated exacerbations
• Stage IV (very severe obstruction or moderate obstruction with 
evidence of chronic respiratory failure): short-acting bronchodilator as 
needed; long-acting bronchodilator(s); cardiopulmonary 
rehabilitation; inhaled glucocorticoids if repeated exacerbation; long-
term oxygen therapy (if criteria met); consider surgical options such as 
lung volume reduction surgery (LVRS) and lung transplantation.
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Management                                     
Medications
• Short-acting beta 2 -agonist bronchodilators (e.g., albuterol, 
metaproterenol, levalbuterol, pirbuterol)
• Long-acting beta 2 -agonist bronchodilators (e.g., salmeterol, 
formoterol, arformoterol, indacaterol, vilanterol)
• Respiratory anticholinergics (e.g., ipratropium, tiotropium, aclidinium)
• Xanthine derivatives (i.e., theophylline)
• Phosphodiesterase-4 Inhibitors (i.e., roflumilast)
• Inhaled corticosteroids (e.g., fluticasone, budesonide)
• Oral corticosteroids (e.g., prednisone)
• Beta 2 -agonist and anticholinergic combinations (e.g., ipratropium 
and albuterol, umeclidinium bromide/vilanterol inhaled)
• Beta 2 -agonist and corticosteroid combinations (e.g., 
budesonide/formoterol, fluticasone and salmeterol).
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Management                                     
Bronchodilators 1
• Inhaled bronchodilators are the primary medications used and result 
in a small overall benefit
• There are two major types, β2agonists and anticholinergics; both exist 
in long-acting and short-acting forms
• Short-acting agents are recommended on an as needed basis
• In those with more severe disease, long-acting agents are 
recommended
• If long-acting bronchodilators are insufficient, then inhaled 
corticosteroids are typically added
• With respect to long-acting agents, it is unclear if tiotropium (a long-
acting anticholinergic) or long-acting beta agonists (LABAs) are better, 
and it may be worth trying each and continuing the one that worked 
best  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                     
Bronchodilators 2
• There are several short-acting β2 agonists available including 
salbutamol and terbutaline; they provide some relief of symptoms for 
four to six hours
• Long-acting β2 agonists such as salmeterol and formoterol are often 
used as maintenance therapy; when used with inhaled steroids they 
increase the risk of pneumonia
• There are two main anticholinergics used in COPD, ipratropium
and tiotropium; ipratropium is a short-acting agent while tiotropium is 
long-acting
• Anticholinergics can cause dry mouth and urinary tract symptoms ND 
are also associated with increased risk of heart disease and stroke
• Aclidinium, another long acting agent which came to market in 2012, 
has been used as an alternative to tiotropium.
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                     
Corticosteroids
• Corticosteroids are usually used in inhaled form but may also be used 
as tablets to treat and prevent acute exacerbations
• While inhaled corticosteroids (ICS) have not shown benefit for people 
with mild COPD, they decrease acute exacerbations in those with 
either moderate or severe disease
• By themselves ICS have no effect on overall one-year mortality
• When used in combination with a LABAs they may decrease mortality 
compared to either ICS or LABAs alone
• Inhaled steroids are associated with increased rates of pneumonia
• Long-term treatment with steroid tablets is associated with significant 
side effects.
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                        
Other medication
• Long-term antibiotics, specifically those from the macrolide class such 
as erythromycin, reduce the frequency of exacerbations in those who 
have two or more a year
• This practice may be cost effective in some areas of the world
• Concerns include that of antibiotic resistance and hearing problems 
with azithromycin
• Methylxanthines such as theophylline generally cause more harm 
than benefit and thus are usually not recommended, but may be used 
as a second-line agent in those not controlled by other measures
• Mucolytics may help to reduce exacerbations in some people with 
chronic bronchitis
• Cough medicines are not recommended.
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                        
Oxygen
• Supplemental oxygen is recommended in those with low oxygen levels 
at rest (a partial pressure of oxygen of less than 50–55 mmHg or 
oxygen saturations of less than 88%)
• In those with normal or mildly low oxygen levels, oxygen 
supplementation may improve shortness of breath
• There is a risk of fires and little benefit when those on oxygen 
continue to smoke
• During acute exacerbations, many require oxygen therapy; the use of 
high concentrations of oxygen without taking into account a person's 
oxygen saturations may lead to increased levels of carbon dioxide and 
worsened outcomes
• In those at high risk of high carbon dioxide levels, oxygen saturations 
of 88–92% are recommended, while for those without this risk 
recommended levels are 94–98%.
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                        
Exacerbations 1
• Acute exacerbations are typically treated by increasing the use of 
short-acting bronchodilators; this commonly includes a combination 
of a short-acting inhaled beta agonist and anticholinergic
• These medications can be given either via a metered-dose 
inhaler with a spacer or via a nebulizer with both appearing to be 
equally effective
• Nebulization may be easier for those who are more unwell 
• Oral corticosteroids improve the chance of recovery and decrease the 
duration of symptoms; 5 days of steroids work as well as 10 - 14.
• In those with a severe exacerbation, antibiotics improve outcomes 
( amoxicillin, doxycycline and azithromycin)
• The FDA recommends against the use of fluoroquinolones when other 
options are available due to higher risks of serious side effects  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                        
Exacerbations 2
• There is no clear evidence for those with less severe cases
• For those with respiratory failure with acutely raised CO2 levels non-
invasive positive pressure ventilation decreases the probability of 
death or the need of intensive care admission
• Additionally, theophylline may have a role in those who do not 
respond to other measures
• Fewer than 20% of exacerbations require hospital admission
• In those without acidosis from respiratory failure, home 
care ("hospital at home") may be able to help avoid some admissions.
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management





Management                                        
Surgery
• For those with very severe disease, surgery is sometimes helpful and 
may include lung transplantation or lung volume reduction surgery
• Lung volume reduction surgery involves removing the parts of the 
lung most damaged by emphysema allowing the remaining, relatively 
good lung to expand and work better
• Volume reduction surgery seems to be particularly effective if 
emphysema predominantly involves the upper lobe, but the 
procedure increases the risks of early death and adverse events
• Lung transplantation is sometimes performed for very severe COPD, 
particularly in younger individuals.
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management
Management                                     
Pulmonary Rehabilitation
• Patient and family education
• Smoking cessation
• Medical management (including oxygen and immunization)
• Respiratory and chest physiotherapy




Management                                     
Patient Education
• It is important to educate the patient with COPD about the disease 
and to encourage his or her active participation in therapy
• The 2 most essential points for the patient to understand are as 
follows:
• The dangers of smoking and the improvement in quality of life 
attainable with smoking cessation
• The need to seek medical care early during an exacerbation and to 
not wait until they are in distress.
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1
Prognosis
• COPD is a chronic, progressive disease showing great variation in its 
natural history
• Spirometry providing data on FEV 1 and FVC is the most common 
measure of disease progression
• A large cohort of patients with COPD of GOLD stage II+ followed up 
every 6 months for 3 years showed a mean annual decline in FEV 1 of 
33 mL
• An annual decline in FEV 1 >40 mL was seen in 38% of the patients, 
while 8% showed an average annual increase of 20 mL
• Current smoking and emphysema are related to more rapid decline in 
FEV 1 .
• Factors that indicate a poor prognosis are frequent exacerbations, 
respiratory insufficiency, nutritional status and comorbidities. 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/
Prophylaxis
• Identification and reduction of exposure to risk factors are important 
steps in the prevention and treatment of COPD
• All individuals who smoke should be encouraged to quit regardless of 
their disease status
• Smokers without COPD should be offered smoking-cessation advice 
• Preventing passive smoking in fetal and early life is important to 
reduce the risk of COPD in adult life
• Reduction of exposure to smoke from indoor biomass combustion, 
particularly among women and children, is important to reduce the 
prevalence of COPD 
• Prevention of COPD exacerbations is important: influenza and 
pneumococcal vaccination as well as treatment with inhaled long-
acting bronchodilators and inhaled corticosteroids all work to reduce 




ABG - Arterial Blood Gas 
COPD - Chronic Obstructive Pulmonary Disease
FEV1 - forced expiratory volume in 1 second
ICS -inhaled corticosteroids 
LABAs - long-acting beta agonists
Diagnostic and treatment guidelines
Diagnosis and Management of Stable Chronic Obstructive Pulmonary 
Disease: A Clinical Practice Guideline Update from the American College 
of Physicians, American College of Chest Physicians, American Thoracic 
Society, and European Respiratory Society
Treatment of Stable Chronic Obstructive Pulmonary Disease: the GOLD 
Guidelines
Chronic obstructive pulmonary disease: Management of chronic 
obstructive pulmonary disease in adults in primary and secondary care
Chronic obstructive pulmonary disease in over 16s: diagnosis and 
management
Chronic-Obstructive-Pulmonary-Disease
